Clinical trial · Observational
Intense Monitoring Study on Tyvyt
Intense Monitoring Study on Sintilimab Injection (Tyvyt®)
NCT04237233CI-TRIAL-00060890unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is a multi-center, prospective, non-interventional and observational study, and will collect data on the safety and efficacy of Tyvyt® in the treatment of Chinese patients with relapsed or refractory classical Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory Classical Hodgkin's Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Incidence of known adverse drug reactions
- timeFrame
- During the actual Tyvyt treatment time.
- measure
- Occurrence of new adverse drug reactions
- timeFrame
- During the actual Tyvyt treatment time.
- measure
- Association, risk factors, severity and incidence of immune-related adverse drug reactions/events
- timeFrame
- During the actual Tyvyt treatment time.
- measure
- Association, risk factors, severity and incidence of serious adverse drug reactions
- timeFrame
- During the actual Tyvyt treatment time.
- measure
- Occurrence of adverse drug reactions in special population
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Patients must be able to understand and voluntarily sign the informed consent form (ICF). Patients must provide reliable contact information, including home phone numbers or follow-up phone number, and be voluntary to be followed up. Patients must have agreed to use Tyvyt® to treat the target indication. Exclusion Criteria: Patients refuse to be included in the study or refuse to cooperate. Patients have participated in another interventional studies within 4 weeks prior to enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.